Literature DB >> 12559124

Role of AMPA and NMDA receptors in the nucleus accumbens shell in turning behaviour of rats: interaction with dopamine receptors.

H Ikeda1, G Akiyama, Y Fujii, R Minowa, N Koshikawa, A R Cools.   

Abstract

The role of AMPA and NMDA receptors in the shell of the nucleus accumbens in turning behaviour of rats was investigated. Unilateral injection of the AMPA receptor agonist, AMPA (0.25, 0.4, 0.5 and 1 microg), into the shell of the nucleus accumbens dose-dependently produced contraversive pivoting, namely tight head-to-tail turning marked by abnormal hindlimb backward stepping, while injection of AMPA (0.5 microg) into the core produced only a marginal effect. This shell-specific AMPA effect was dose-dependently inhibited by the AMPA receptor antagonist, NBQX (1 and 10 ng), which alone did not produce turning behaviour. The AMPA-induced pivoting was also dose-dependently inhibited by the non-competitive NMDA receptor antagonist, MK-801 (0.1 and 0.5 microg). Neither MK-801 (0.1, 0.5 and 5 microg) nor the NMDA receptor agonist, NMDA (0.5 and 1 microg), injected unilaterally into the shell, produced turning behaviour. Unilateral injection of a mixture of dopamine D(1) (SKF 38393, 5 microg) and D(2) (quinpirole, 10 microg) receptor agonists into the shell has been found to elicit contraversive pivoting. The dopamine D(1)/D(2) receptor antagonist, cis-(Z)-flupentixol (1 and 10 microg), injected into the shell, in doses known to block dopamine D(1)/D(2) receptor-mediated pivoting, also significantly inhibited AMPA (0.5 microg)-induced pivoting. Moreover, both NBQX (1 and 10 ng) and MK-801 (0.1 and 0.5 microg), injected into the shell, significantly inhibited dopamine D(1)/D(2) receptor-mediated pivoting. It is therefore concluded that unilateral stimulation of AMPA receptors in the shell of the nucleus accumbens can elicit contraversive pivoting, and that both AMPA and dopamine D(1)/D(2) receptors play a critical role in shell-specific pivoting in contrast to NMDA receptors that at best play only a modulatory role.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559124     DOI: 10.1016/s0028-3908(02)00334-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Dopamine-glutamate interplay in the ventral striatum modulates spatial learning in a receptor subtype-dependent manner.

Authors:  Roberto Coccurello; Alberto Oliverio; Andrea Mele
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

2.  Lateral preoptic and ventral pallidal roles in locomotion and other movements.

Authors:  Suriya Subramanian; Rhett A Reichard; Hunter S Stevenson; Zachary M Schwartz; Kenneth P Parsley; Daniel S Zahm
Journal:  Brain Struct Funct       Date:  2018-04-26       Impact factor: 3.270

3.  Mu-opioid stimulation in rat prefrontal cortex engages hypothalamic orexin/hypocretin-containing neurons, and reveals dissociable roles of nucleus accumbens and hypothalamus in cortically driven feeding.

Authors:  Jesus D Mena; Ryan A Selleck; Brian A Baldo
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

Review 4.  Feeding-modulatory effects of mu-opioids in the medial prefrontal cortex: a review of recent findings and comparison to opioid actions in the nucleus accumbens.

Authors:  Ryan A Selleck; Brian A Baldo
Journal:  Psychopharmacology (Berl)       Date:  2017-01-04       Impact factor: 4.530

Review 5.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

6.  Impulsive behaviour induced by both NMDA receptor antagonism and GABAA receptor activation in rat ventromedial prefrontal cortex.

Authors:  Emily R Murphy; Anushka B P Fernando; Gonzalo P Urcelay; Emma S J Robinson; Adam C Mar; David E H Theobald; Jeffrey W Dalley; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2011-11-19       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.